血管移植物感染(VGI)仍然是重要的并发症,具有很高的死亡率和发病率。目前,关注血管移植物涂层在预防VGI中的作用的研究很少。因此,这项研究的目的是调查和总结临床前体内模型的关键特征,这些模型已用于研究预防VGI的涂层策略,并建立可用于未来临床前研究的理想模型。
根据系统评价和荟萃分析指南的首选报告项目进行系统评价。在MEDLINE(PubMed)中进行了全面搜索,Embase,和WebofScience。
对于每个数据库,制定了具体的搜索策略。使用毒理学数据可靠性评估工具(ToxRTool)评估质量。动物模型的类型,移植,涂层,和病原体进行了总结。评估每个研究中的结果评估。
总共,确定了4667项研究,其中包括94篇专注于体内测试的论文。金黄色葡萄球菌是最常用的生物(n=65;67.7%)。大多数接枝类型是聚酯接枝。利福平是最常用的抗生素涂层(n=43,48.3%)。在结果评估中,大多数研究提到菌落形成单位计数(n=88;91.7%)和临床结局(n=72;75%).根据ToxRTool的说法,21(22.3%,n=21/94)研究被认为是不可靠的。
目前公布的体内模型非常杂。在将新型移植涂层转移到临床实践中时,应更加注意这些临床前报告的方法。临床前报告中使用的变量(细菌菌株,活性涂层的持续时间)与当前的临床研究不一致。根据这篇综述的结果,为血管移植物涂层的抗感染性能的临床前体内测试提供了一个完整和全面的设置。
Vascular graft infection (VGI) remains an important complication with a high mortality and morbidity rate. Currently, studies focusing on the role of vascular graft coatings in the prevention of VGI are scarce. Therefore, the aims of this study were to survey and summarise key features of pre-clinical in vivo models that have been used to investigate coating strategies to prevent VGI and to set up an ideal model that can be used in future preclinical research.
A systematic
review was conducted in accordance with the Preferred reporting items for Systematic Reviews and Meta-Analysis guidelines. A comprehensive search was performed in MEDLINE (PubMed), Embase, and Web of Science.
For each database, a specific search strategy was developed. Quality was assessed with the Toxicological data Reliability Assessment Tool (ToxRTool). The type of animal model, graft, coating, and pathogen were summarised. The outcome assessment in each study was evaluated.
In total, 4 667 studies were identified, of which 94 papers focusing on in vivo testing were included. Staphylococcus aureus was the organism most used (n = 65; 67.7%). Most of the graft types were polyester grafts. Rifampicin was the most frequently used antibiotic coating (n = 43, 48.3%). In the outcome assessment, most studies mentioned colony forming unit count (n = 88; 91.7%) and clinical outcome (n = 72; 75%). According to the ToxRTool, 21 (22.3%, n = 21/94) studies were considered to be not reliable.
Currently published in vivo models are very miscellaneous. More attention should be paid to the methodology of these pre-clinical reports when transferring novel graft coatings into clinical practice. Variables used in pre-clinical reports (bacterial strain, duration of activity coating) do not correspond well to current clinical studies. Based on the results of this
review, a proposal for a complete and comprehensive set up for pre-clinical invivo testing of anti-infectious properties of vascular graft coatings was defined.